Erasca, Inc. (common stock, CUSIP 29479A108) is the subject of a joint Schedule 13G/A filed by multiple Frazier Life Sciences entities and individuals disclosing beneficial holdings of the issuer's common stock. Frazier Life Sciences Public Fund, L.P. directly holds 15,038,753 shares (5.3% of the class) based on 283,287,382 shares outstanding as of May 6, 2025. Additional Frazier vehicles report direct holdings of 2,405,634 shares (0.8%), 1,674,681 shares (0.6%), and 3,610,368 shares (1.3%) respectively.
The filing clarifies voting and dispositive power: the reporting persons state no sole voting or dispositive power over the disclosed shares and report shared voting and dispositive power for those amounts. The statement also corrects prior attributions, removing previously attributed ownership for certain committee members and clarifying the managerial structures that determine who shares investment authority.
Positive
FLSPF reports a material holding of 15,038,753 shares, equal to 5.3% of outstanding common stock
The filing clarifies and corrects prior attributions, improving transparency of actual beneficial ownership
Negative
No reporting person claims sole voting or dispositive power; holdings are reported as shared rather than controlled
The amendment indicates previous overstatements of individual attributions, reflecting prior disclosure inaccuracies
Insights
TL;DR: Frazier entities disclose a material >5% stake by FLSPF and additional mid-single-digit holdings across affiliated funds.
The Schedule 13G/A documents that Frazier Life Sciences Public Fund, L.P. holds 15,038,753 shares, representing 5.3% of Erasca's outstanding common stock using the issuer's May 6, 2025 share count. Several affiliated funds report smaller but non-trivial positions ranging from 0.6% to 1.3%. All disclosed holdings are reported as shared voting and dispositive power, not sole control, and the filing expressly corrects prior over-attributions to individual committee members. For investors, this clarifies the distribution of ownership among related investment vehicles and confirms the absence of an asserted controlling position by these reporting persons.
The amendment emphasizes governance structure: several general partners and manager entities conduct decisions via investment committees, and the filing corrects prior statements that attributed direct beneficial ownership to individual committee members. The document shows shared rather than sole authority over votes and dispositions for the reported shares, which is material for assessing potential influence but does not assert a concerted control group. This provides greater transparency about who legally exercises voting and investment power within the Frazier family of funds.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Erasca, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
29479A108
(CUSIP Number)
06/30/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
Frazier Life Sciences Public Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
15,038,753.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
15,038,753.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
15,038,753.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
FHMLSP, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
15,038,753.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
15,038,753.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
15,038,753.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
FHMLSP, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
15,038,753.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
15,038,753.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
15,038,753.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
Frazier Life Sciences Public Overage Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,405,634.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,405,634.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,405,634.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.8 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
FHMLSP Overage, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,405,634.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,405,634.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,405,634.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.8 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
FHMLSP Overage, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,405,634.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,405,634.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,405,634.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.8 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
Frazier Life Sciences X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,674,681.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,674,681.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,674,681.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
FHMLS X, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,674,681.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,674,681.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,674,681.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
FHMLS X, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,674,681.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,674,681.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,674,681.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
Frazier Life Sciences XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,610,368.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,610,368.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,610,368.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
FHMLS XI, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,610,368.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,610,368.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,610,368.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
FHMLS XI, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,610,368.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,610,368.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,610,368.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.3 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
James N. Topper
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,674,681.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,674,681.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,674,681.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of 1,674,681 shares of Common Stock held directly by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
Patrick J. Heron
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,674,681.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,674,681.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,674,681.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.6 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The shares listed in rows 6, 8 and 9 consist of 1,674,681 shares of Common Stock held directly by Frazier Life Sciences X, L.P.
The percentage listed in row 11 is calculated based on 283,287,382 shares of Common Stock outstanding on May 6, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 13, 2025.
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
Albert Cha
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
James Brush
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
29479A108
1
Names of Reporting Persons
Daniel Estes
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Erasca, Inc.
(b)
Address of issuer's principal executive offices:
3115 Merryfield Row, Suite 300, San Diego, CA, 92121.
Item 2.
(a)
Name of person filing:
The entities and persons filing this statement (collectively, the "Reporting Persons") are:
Frazier Life Sciences Public Fund, L.P. ("FLSPF")
FHMLSP, L.P.
FHMLSP, L.L.C.
Frazier Life Sciences Public Overage Fund, L.P. ("FLSPOF")
FHMLSP Overage, L.P.
FHMLSP Overage, L.L.C.
Frazier Life Sciences X, L.P. ("FLS X")
FHMLS X, L.P.
FHMLS X, L.L.C.
Frazier Life Sciences XI, L.P. ("FLS XI")
FHMLS XI, L.P.
FHMLS XI, L.L.C.
James N. Topper ("Topper")
Patrick J. Heron ("Heron")
Albert Cha ("Cha")
James Brush ("Brush")
Daniel Estes ("Estes" and together with Topper, Heron, Cha and Brush, the "Members")
(b)
Address or principal business office or, if none, residence:
The address of the principal place of business for each of the Reporting Persons is:
c/o Frazier Life Sciences Management, L.P.
1001 Page Mill Rd, Building 4, Suite B
Palo Alto, CA 94304
(c)
Citizenship:
The information contained in row 4 of each Reporting Person's cover page to this Statement is incorporated by reference.
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
29479A108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained in row 9 of each Reporting Person's cover page to this Statement (including the footnotes thereto) is incorporated by reference.
FLSPF directly holds 15,038,753 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
FLSPOF directly holds 2,405,634 shares of Common Stock. FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
FLS X directly holds 1,674,681 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X.
FLS XI directly holds 3,610,368 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Statement corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.
Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Statement or a member of a "group" with any other person.
(b)
Percent of class:
The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Frazier Life Sciences Public Fund, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:
08/14/2025
FHMLSP, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:
08/14/2025
FHMLSP, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:
08/14/2025
Frazier Life Sciences Public Overage Fund, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.
Date:
08/14/2025
FHMLSP Overage, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.
Date:
08/14/2025
FHMLSP Overage, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.
Date:
08/14/2025
Frazier Life Sciences X, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.
Date:
08/14/2025
FHMLS X, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.
Date:
08/14/2025
FHMLS X, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS X, L.L.C.
Date:
08/14/2025
Frazier Life Sciences XI, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:
08/14/2025
FHMLS XI, L.P.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:
08/14/2025
FHMLS XI, L.L.C.
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:
08/14/2025
James N. Topper
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:
08/14/2025
Patrick J. Heron
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017
Date:
08/14/2025
Albert Cha
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:
08/14/2025
James Brush
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021
Date:
08/14/2025
Daniel Estes
Signature:
/s/ Steve R. Bailey
Name/Title:
By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022
Date:
08/14/2025
Exhibit Information
Exhibit 99.1 Joint Filing Agreement, dated as of May 15, 2025, incorporated by reference into this Statement.
A group of Frazier Life Sciences entities and related individuals, including Frazier Life Sciences Public Fund, L.P., FHMLSP entities, Frazier Life Sciences Public Overage Fund, Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P., and individuals James N. Topper, Patrick J. Heron, Albert Cha, James Brush and Daniel Estes.
How many Erasca shares does Frazier Life Sciences Public Fund, L.P. report owning?
15,038,753 shares, representing 5.3% of the common stock based on 283,287,382 shares outstanding as of May 6, 2025.
What percentage of Erasca does Frazier Life Sciences XI, L.P. hold?
Frazier Life Sciences XI, L.P. directly holds 3,610,368 shares, representing 1.3% of the class per the filing.
Do any reporting persons claim sole voting or dispositive power over the shares?
No. The filing states 0 shares of sole voting power and 0 shares of sole dispositive power for each reporting person; all reported powers are shared.
What correction does this Schedule 13G/A make to prior filings?
The amendment clarifies that certain investment committee members should not be attributed beneficial ownership of shares held by the funds, correcting prior overstatements of individual attributions.
What share count was used to calculate percentages in the filing?
Percentages are calculated using 283,287,382 shares outstanding on May 6, 2025, as disclosed in the issuer's May 13, 2025 Quarterly Report.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
You have made too many password recovery requests. Please try again tomorrow.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
